Special Issue

Advances in Gynecological Oncology: From Pathogenesis to Therapy: 2nd Edition

Message from the Guest Editor

The histological categories of some gynecological tumors do not accurately differentiate the clinical course and response to therapy. It is also now evident that molecular characteristics affect the biological behavior and chemo-sensitivity of ovarian carcinomas. Advanced cervical cancer and recurrences respond poorly to chemotherapy. There is a further need to identify better biomarkers that allow for personalized therapy and combined therapeutic regimens, including immunotherapy, radiation therapy and chemotherapy, and personalized fertility-sparing treatment in young women should be considered when feasible. This Special Issue aims to gather reviews and original contributions in one collection to illustrate recent advances in gynecological cancers and the future directions of clinical and basic research.

Guest Editor

Dr. Andrea Ciavattini

Woman's Health Sciences Department, Universita Politecnica delle Marche, 60121 Ancona, Italy

Deadline for manuscript submissions

closed (18 December 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/197446

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

